As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
15 Analysts have issued a Zentalis Pharmaceuticals Inc forecast:
15 Analysts have issued a Zentalis Pharmaceuticals Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 27 27 |
34%
34%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -152 -152 |
27%
27%
|
|
| EBIT (Operating Income) EBIT | -153 -153 |
27%
27%
|
|
| Net Profit | -149 -149 |
17%
17%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Zentalis Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of breast cancer. The company is also developing ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, LLC was founded in 2014 and is based in New York, New York.
| Head office | United States |
| CEO | Julia Eastland |
| Employees | 166 |
| Founded | 2014 |
| Website | www.zentalis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


